Marion Hitchcock

USPTO Granted Patents = 14 (Patent Applications = 13)

EPO Patents = 7 (Patent Applications = 23)

Average Co-Inventor Count = 4.7

ph-index = 3

Forward Citations = 21(Granted Patents)

Location History:

Berlin, DE (US) (2014)
Berlin, DE (2015 - 2017)
Brookline, DE (2017)
Brookline, MA (US) (2017 - 2020)

Company Filing History:

8 out of 378

Bayer Pharma Aktiengesellschaft

patents

8 out of 721

Bayer Intellectual Property Gmbh

patents

1 out of 63

Ardea Biosciences, Inc

patents

where one patent can have more than one assignee

Years Active: 2014-2020

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10604532 - Substituted benzylindazoles for use as BUB1 kinase inhibitors in the treatment of hyperproliferative diseases (2020-03-31),

2. 10428044 - 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones (2019-10-01),

3. 10350206 - Benzyl substituted indazoles as BUB1 inhibitors (2019-07-16),

4. 10266548 - Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases (2019-04-23),

5. 9765058 - Substituted benzylpyrazoles (2017-09-19),

6. 9745285 - Heteroaryl substituted pyrazoles (2017-08-29),

7. 9682974 - Heteroaryl substituted pyrazoles (2017-06-20),

8. 9643953 - Substituted benzylpyrazoles (2017-05-09),

9. 9499547 - Amino-substituted imidazopyridazines (2016-11-22),

10. 9381177 - Substituted N-(2-arylamino)aryl sulfonamide-containing combinations (2016-07-05),

11. 9045429 - Substituted phenoxypyridines (2015-06-02),

12. 8993630 - Substituted sulphonamido phenoxybenzamides (2015-03-31),

13. 8962606 - Substituted benzosulphonamides (2015-02-24),

14. 8673919 - Dihydropyridin sulfonamides and dihydropyridin sulfamides as MEK inhibitors (2014-03-18),

Title: The Innovative Mind of Marion Hitchcock: A Pioneer in Pharmaceutical Patents

Introduction: Marion Hitchcock, a distinguished inventor based in Berlin, Germany, has made significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 13 patents, she has dedicated her research to the development of innovative compounds that target critical biological pathways.

Latest Patents: Among her most recent inventions are two notable patents focusing on BUB1 kinase inhibitors. The first patent covers substituted benzylindazoles that serve as inhibitors of BUB1 kinase, specifically addressing hyperproliferative diseases. The second patent introduces 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones, which also function as BUB1 kinase inhibitors, detailing their production processes and therapeutic uses.

Career Highlights: Marion's professional journey includes significant tenures at prominent companies such as Bayer Pharma and Bayer Intellectual Property GmbH. Her work in these organizations has played a vital role in advancing pharmaceutical research and patent development.

Collaborations: Throughout her career, Marion has collaborated with notable colleagues like Gerhard Siemeister and Hans Briem. These partnerships have enriched her research efforts, leading to groundbreaking discoveries in the pharmaceutical domain.

Conclusion: Marion Hitchcock exemplifies the essence of innovation in the pharmaceutical industry. Her extensive patent portfolio and collaborative spirit continue to inspire future generations of inventors and researchers dedicated to improving health outcomes through advanced scientific discoveries.

This text is generated by artificial intelligence and may not be accurate.